Skip to main content

Acute GVHD Diagnostics, Leveraging Biomarkers in Patient Treatment

A leader in the industry, Dr. Ferrara’s career has focused on the immunology of BMT, particularly its major complication GVHD. Using innovative proteomic techniques, his team has identified and validated biomarkers for skin, gut and steroid-resistant GVHD. Eurofins Viracor is exclusively partnering with Dr. Ferrara to utilize the approach developed by Drs. Ferrara and Levine and the Mount Sinai Acute GVHD International Consortium (MAGIC).

Learn how the Pre-Symptomatic, Symptom Onset, and Post-Treatment algorithms can predict if Hematopoietic Cell Transplant patients (HCT) are at high risk for non-relapse mortality and acute graft-versus-host disease.

Dr. Ferrara discusses the biology of the biomarkers utilized in the aGVHD Algorithm testing (REG-3α and ST2), explaining how they act as a “liquid biopsy” of the GI tract.

In addition, Dr. Ferrara explores three different clinical scenarios where utilization of the aGVHD algorithm tests could predict non-relapse mortality and aGVHD. While reviewing example reports for each clinical scenario, Dr. Ferrara recommends the desired approach for treatment.

Length of Presentation: 56 minutes

Presented by: 

  • Dr. James Ferrara, MD
    Ward-Coleman Chair in Cancer Medicine
    Professor of Pediatrics & Medicine
    Icahn School of Medicine at Mount Sinai


Back to top